

In The Claims:

Please cancel claims 68-88 and 132-145 without prejudice.

Please add the following claims:

146. (New) The insulin derivative of claim 100, wherein the lipophilic substituent is tetradecanoyl.

147. (New) A pharmaceutical composition which is an aqueous solution, comprising (a) the insulin derivative of claim 146, (b) an isotonic agent, (c) a preservative and (d) a buffer.

148. (New) The pharmaceutical composition of claim 147, wherein the pH of the aqueous solution is in the range of 6.5-8.5.

149. (New) The pharmaceutical composition of claim 147, wherein the solubility of the insulin derivative exceeds 600 nmol/ml of the aqueous solution.

150. (New) The pharmaceutical composition of claim 147, further comprising an insulin or an insulin analogue which has a rapid onset of action.

151. (New) The pharmaceutical composition of claim 147, wherein the insulin derivative is in the form of a hexamer.

152. (New) A method of treating diabetes in a patient in need of such a treatment comprising administering to the patient a therapeutically effective